Fosamax Manufacturing, Supply & Shortage History

How Alendronate Works: Mechanism of Action

Alendronate is a nitrogen-containing bisphosphonate that binds hydroxyapatite on actively resorbing bone surfaces, where osteoclasts internalize it during normal bone turnover. Once inside the osteoclast, the drug inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway that produces lipid anchors required for signaling proteins like Ras, Rho, and Rac [1]. Without these prenylated GTPases, the osteoclast loses its ruffled border, detaches from bone, and undergoes apoptosis.

This targeted disruption is what separates nitrogen-containing bisphosphonates from older, non-nitrogen analogs like etidronate, which work through a less specific cytotoxic ATP analog mechanism [2]. The selectivity matters clinically. Alendronate suppresses bone resorption markers (urinary N-telopeptide, serum C-telopeptide) by 50 to 70% within 3 to 6 months while preserving osteoblast-driven bone formation to a lesser degree, producing a net gain in bone mineral density (BMD) of 5 to 8% at the lumbar spine over 3 years [3].

The drug's skeletal half-life exceeds 10 years, meaning residual bisphosphonate remains embedded in bone matrix long after a patient stops taking it. This pharmacokinetic property is the basis for bisphosphonate "drug holidays," which the American Society for Bone and Mineral Research (ASBMR) endorsed in a 2016 task force report for patients at moderate fracture risk after 5 years of oral therapy [4].

The FIT Trial and Clinical Foundation

The Fracture Intervention Trial (FIT) established the fracture-reduction evidence that made alendronate a first-line osteoporosis therapy worldwide. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 with low femoral-neck BMD but no baseline vertebral fractures [3]. Over 4 years, alendronate 5 mg daily (increased to 10 mg at year 3) reduced the risk of radiographic vertebral fractures by 47% compared with placebo (RR 0.53 to 95% CI 0.41 to 0.68).

FIT also demonstrated a 30% reduction in clinical fractures overall. Hip fracture reduction did not reach statistical significance in the non-vertebral-fracture arm alone, but a pre-specified pooled analysis of both FIT arms (N=6,459) showed a 51% hip fracture risk reduction in women with femoral-neck T-scores of −2.5 or below [3].

These data, combined with the FOSIT trial in 1,908 postmenopausal women across 34 countries showing BMD gains of 4.9% at the lumbar spine at 12 months, provided the registration package Merck used to secure approvals globally [5]. The weekly 70 mg formulation, approved in 2000 based on bioequivalence studies, became the dominant prescribed dose because of improved adherence over daily dosing.

Merck's Original Manufacturing and Patent Timeline

Merck developed alendronate sodium at its Rahway, New Jersey research campus during the late 1980s, synthesizing it as part of a broader bisphosphonate program. The compound received U.S. Patent 4,922,007, filed in 1988, covering the alendronate molecule itself. A subsequent formulation patent (U.S. Patent 5,994,329) covered the once-weekly 70 mg tablet and extended market exclusivity.

The FDA approved Fosamax in October 1995 for the treatment of osteoporosis in postmenopausal women, followed by approvals for osteoporosis prevention (1997), glucocorticoid-induced osteoporosis (1999), male osteoporosis (2000), and Paget's disease. At peak sales in 2007, Fosamax generated approximately $3.1 billion annually for Merck, making it one of the top-grossing osteoporosis drugs in pharmaceutical history.

Primary manufacturing took place at Merck facilities in the United States and Puerto Rico, with active pharmaceutical ingredient (API) sourcing from both internal synthesis and contract manufacturers. The Merck Elkton, Virginia plant and the Barceloneta, Puerto Rico facility handled significant portions of finished-dose production through Merck's vertically integrated supply chain.

Patent Expiration and the Generic Flood (2008 Onward)

Alendronate's core compound patent expired in February 2008. Teva Pharmaceutical Industries was among the first to file an Abbreviated New Drug Application (ANDA) and launched a generic 70 mg tablet almost immediately. Within 18 months, more than ten generic manufacturers had entered the U.S. market.

The speed of generic entry was notable. By mid-2009, generic alendronate captured over 80% of total prescriptions. Branded Fosamax revenue dropped from $3.1 billion in 2007 to under $600 million by 2010, a pattern consistent with Paragraph IV "first-to-file" generic competition for high-volume oral solids.

Current manufacturers with approved ANDAs listed in the FDA Orange Book include Teva, Sun Pharmaceutical, Aurobindo Pharma, Amneal Pharmaceuticals, Mylan (now Viatris), Apotex, Cipla, Lupin, Dr. Reddy's Laboratories, Zydus Lifesciences, and several others [6]. Most API for these generics is synthesized in India and China, with finished-dose manufacturing split between facilities in India, the United States, and occasionally Europe.

This geographic concentration of API production is a recurring vulnerability. When Chinese environmental regulations forced temporary shutdowns of chemical synthesis plants in Zhejiang and Jiangsu provinces during 2017 to 2018, multiple bisphosphonate raw materials saw price spikes and allocation constraints that rippled through downstream tablet manufacturers.

FDA Shortage Records and Supply Disruptions

The FDA Drug Shortage Database has logged several distinct alendronate supply events since 2010. These shortages have primarily affected specific strengths or specific manufacturers rather than causing a total market-wide stockout.

The first significant disruption occurred in 2012 to 2013, when Apotex temporarily halted production of its alendronate 35 mg and 70 mg tablets due to manufacturing quality issues identified during an FDA inspection. The Apotex facility in Signet Chemicals (India), which supplied API, received a warning letter that forced reformulation and revalidation. During this period, other manufacturers absorbed demand, and the shortage resolved within approximately 6 months.

A second notable event happened in 2017, overlapping with the broader Chinese API disruptions mentioned above. Several generic alendronate manufacturers reported allocation-based distribution, meaning wholesalers received less than ordered quantities. The shortage was classified as "currently in shortage" on the FDA database for the 5 mg and 10 mg daily-dose tablets, which have lower market volume and fewer active manufacturers than the 70 mg weekly formulation.

The 5 mg and 10 mg strengths remain more vulnerable to shortages than the 70 mg tablet because fewer manufacturers produce them, and demand is lower. Pediatric and Paget's disease dosing requires these strengths, so their unavailability disproportionately affects smaller patient populations.

A 2022 shortage episode affected Teva's alendronate 70 mg tablets specifically, attributed to "manufacturing delays" without further public specification. Teva resolved the shortage within 3 months, and the FDA removed it from the active shortage list in early 2023.

"Bisphosphonate shortages tend to be manufacturer-specific rather than class-wide, because the generic market is broad enough to absorb single-supplier disruptions," noted the American Society of Health-System Pharmacists (ASHP) in its 2023 Drug Shortage Statistics report [7].

Raw Material and API Supply Chain

Alendronate sodium synthesis requires phosphorous trichloride, 4-aminobutyric acid, and triethyl phosphite as key starting materials. The reaction pathway involves a two-step process: formation of the aminoalkyl-bisphosphonic acid backbone, followed by sodium salt crystallization and milling to pharmaceutical-grade particle size.

Over 70% of global alendronate API production is concentrated among approximately 8 facilities in Gujarat (India) and Jiangsu (China), according to data compiled from FDA establishment registration records. This concentration creates single-point-of-failure risks. When India's Central Drugs Standard Control Organisation (CDSCO) suspended a manufacturing license for one Gujarat API plant in 2019 over data integrity findings, three downstream ANDA holders experienced temporary supply gaps.

Quality control for bisphosphonate APIs is particularly demanding because residual phosphonate impurities can affect bioavailability and tolerability. The United States Pharmacopeia (USP) monograph for alendronate sodium specifies limits on seven identified impurities, with total impurities capped at 1.0% [8]. Manufacturers that fail to meet these thresholds during stability testing may need to discard entire batches, contributing to intermittent supply tightness.

Current Availability and Pricing

As of early 2026, alendronate is not listed on the FDA's active drug shortage database, and all major strengths (5 mg, 10 mg, 35 mg, 40 mg, 70 mg) are available from multiple manufacturers. The 70 mg once-weekly tablet dominates prescribing, accounting for over 90% of alendronate dispensing volume.

Retail cash prices for generic alendronate 70 mg (4 tablets, a one-month supply) range from $4 to $15 at most U.S. pharmacies, making it one of the least expensive branded-to-generic osteoporosis therapies available. Many pharmacy discount programs and Medicare Part D plans cover alendronate at the lowest copay tier.

"For formulary committees evaluating osteoporosis drug budgets, alendronate remains the cost-effectiveness benchmark against which newer agents like denosumab and romosozumab are measured," according to the 2020 Endocrine Society Clinical Practice Guideline on osteoporosis management [9].

By comparison, branded Prolia (denosumab) carries a wholesale acquisition cost of approximately $1,800 per 6-month injection, and Evenity (romosozumab) costs roughly $1,825 per monthly injection for a 12-month course. The 100-fold price difference between generic alendronate and anabolic agents explains why bisphosphonates remain the global first-line therapy in every major guideline, including those from the AACE/ACE, the Endocrine Society, and NICE [10].

Regulatory and Quality Considerations

The FDA's Office of Pharmaceutical Quality has inspected alendronate manufacturing facilities under both the pre-approval and surveillance programs. Between 2015 and 2024, at least four alendronate ANDA holders received FDA Form 483 observations related to manufacturing process deviations, out-of-specification investigations, or data integrity concerns at their API or finished-dose facilities.

None of these observations resulted in product recalls for alendronate specifically, but they illustrate the ongoing quality pressure on high-volume generic oral solid manufacturers. The FDA's Mutual Recognition Agreements (MRAs) with the European Medicines Agency (EMA) and other regulators have helped distribute inspection workload, particularly for Indian and Chinese facilities producing bisphosphonate APIs.

Tablet dissolution testing is a critical quality attribute for alendronate because the drug is poorly absorbed (oral bioavailability of only 0.64% under fasting conditions) and highly sensitive to formulation differences [11]. The FDA requires ANDA applicants to demonstrate bioequivalence through pharmacokinetic studies measuring urinary excretion of alendronate, a methodology that is more demanding than standard plasma-based bioequivalence testing used for most oral generics.

Supply Chain Resilience: What Has Changed

The COVID-19 pandemic exposed vulnerabilities in pharmaceutical supply chains globally, and bisphosphonates were not exempt. During the first half of 2020, freight disruptions between India and the United States delayed API shipments for several generic manufacturers, though alendronate did not appear on the FDA shortage list during this period because existing inventory buffers proved adequate.

Post-pandemic, several manufacturers have diversified their API sourcing. Teva and Amneal have both disclosed in annual reports that they maintain dual-source API agreements for high-volume generics including alendronate, reducing dependence on any single facility. The FDA's Drug Shortage Task Force report (2019, updated 2020) recommended that manufacturers of essential medications maintain at least 6 months of safety stock, though compliance remains voluntary [12].

The mature generic market for alendronate, with 12 or more active ANDA holders, provides a structural buffer against prolonged shortages. Single-manufacturer shortages typically resolve within 3 to 6 months as competitors increase production. Class-wide shortages (affecting all bisphosphonates simultaneously) have not occurred to date.

Patients prescribed alendronate 70 mg weekly who encounter a pharmacy-level stockout can generally obtain the same strength from an alternative manufacturer within 1 to 3 business days through wholesaler reallocation, or their prescriber can switch to risedronate 35 mg weekly or 150 mg monthly as a therapeutic alternative with equivalent fracture-reduction evidence from the VERT and HIP trials [13].